The Scientist

» CRISPR/Cas

Most Recent

image: CRISPR Antidotes Galore

CRISPR Antidotes Galore

By | June 13, 2016

Anti-CRISPR proteins are prevalent in phage genomes and bacterial mobile genetic elements, researchers show.

0 Comments

image: Creating a DNA Record with CRISPR

Creating a DNA Record with CRISPR

By | June 9, 2016

Researchers repurpose a bacterial immune system to be a molecular recording device.

0 Comments

image: RNA-Targeting CRISPR

RNA-Targeting CRISPR

By | June 2, 2016

Scientists identify a novel CRISPR system that zeroes in on single-stranded RNA.  

2 Comments

image: Screening  with CRISPR

Screening with CRISPR

By | June 1, 2016

Ever-improving CRISPR-based tools are already ripe for large-scale genetic screens.

1 Comment

image: Stem Cell Rules Tackle Human Embryo Editing

Stem Cell Rules Tackle Human Embryo Editing

By | May 17, 2016

A set of international stem cell guidelines recommends that oversight committees at research institutions oversee all research on embryos.

0 Comments

Researchers use a gene editor to introduce an allele that eliminates the horned trait—and thus, the need for an expensive and painful process of dehorning—in dairy cows.

2 Comments

image: With CRISPR, Modeling Disease in Mini Organs

With CRISPR, Modeling Disease in Mini Organs

By | May 6, 2016

Organoids grown from genetically edited stem cells are giving scientists a new tool to screen drugs and test treatments.

0 Comments

image: Mapping Traits to Genes with CRISPR

Mapping Traits to Genes with CRISPR

By | May 5, 2016

Researchers develop a technique to direct chromosome recombination with CRISPR/Cas9, allowing high-resolution genetic mapping of phenotypic traits in yeast.

0 Comments

image: Advances in Genome Editing

Advances in Genome Editing

By | April 20, 2016

Researchers develop a CRISPR-based technique that efficiently corrects point mutations without cleaving DNA.

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. NYU Halts Studies, Suspends Investigator
    The Nutshell NYU Halts Studies, Suspends Investigator

    Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

  2. Exercise-Induced Muscle Factor Promotes Memory
  3. The Meaning of Pupil Dilation
    Daily News The Meaning of Pupil Dilation

    Scientists are using pupil measurements to study a wide range of psychological processes and to get a glimpse into the mind.

  4. Brexit’s Effects on Science